Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 21 February 2018

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Professor Stephen O'Brien Present for all notes
2. Mr Kamal Balakrishnan Present for all notes
3. Mr Michael Chambers Present for all notes
4. Mr David Chandler Present for all notes
5. Ms Gail Coster Present for all notes
6. Dr Prithwiraj Das Present for notes 1-16
7. Dr Natalie Hallas Present for all notes
8. Mr John Hampson Present for all notes
9. Dr Nigel Langford Present for all notes
10. Professor Andrea Manca Present for all notes
11. Dr Richard Nicholas Present for all notes
12. Prof Andrew Renehan Present for all notes
13. Dr Peter Selby Present for all notes
14. Professor Matt Stevenson Present for all notes
15. Dr Paul Tappenden Present for all notes
16. Dr Derek Ward Present for all notes
17. Dr Judith Wardle Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Stephanie Callaghan Project Manager, National Institute for Health and Care Excellence Present for all notes

Tanith Musson Administrator, National Institute for Health and Care Excellence Present for all notes

Sana Khan Technical Analyst, National Institute for Health and Care Excellence Present for notes 1-16
The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of cenegermin for treating neurotrophic keratitis [ID946], crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [ID1098], and atezolizumab for treating non-small-cell lung cancer after platinum-
based chemotherapy [ID970].

2. The Chair welcomed Dr Natalie Hallas to their first meeting as a member of the Appraisal Committee.

3. The Chair informed the Committee of the non-public observers at this meeting: Jenny Craven, Christopher Eatough, Clare Harland, Nicola Hay, Gareth Murphy, Catherine Quigley, Abi Senthinathan and Julia Sus.

4. Apologies were received from Professor Robert Walton.

**Appraisal of cenebergermin for treating neurotrophic keratitis [ID946]**

**Part 1 – Open session**

5. The Chair welcomed the invited experts: Francisco Figueiredo, Nigel Fleeman, James Mahon, and Saaeha Rauz to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Dompé to the meeting.

7. The Chair asked all Committee members to declare any relevant interests.

   7.1. Mr Kamal Balakrishnan, Mr Michael Chambers, Mr David Chandler, Ms Gail Coster, Dr Prithviraj Das, Dr Natalie Hallas, Mr John Hampson, Dr Nigel Langford, Professor Andrea Manca, Dr Richard Nicholas, Prof Andrew Renehan, Prof Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden, Dr Derek Ward, and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cenebergermin for treating neurotrophic keratitis [ID946].

8. The Chair asked all NICE Staff to declare any relevant interests.

   8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cenebergermin for treating neurotrophic keratitis [ID946].

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

   9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cenebergermin for treating neurotrophic keratitis [ID946].

   9.2. Ms Saaeha Rauz declared a personal non-specific non-financial interest as she sits on the clinical reference group for ophthalmology.
9.2.1. It was agreed that this declaration would not prevent Ms Saaeha Rauz from participating in this section of the meeting

10. The Chair introduced the lead team, Professor Andrea Manca, Dr Richard Nicholas and Dr Judith Wardle, who gave presentations on the clinical effectiveness and cost effectiveness of cenegermin for treating neurotrophic keratitis [ID946]

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of cenegermin for treating neurotrophic keratitis [ID946]

15.1. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Appraisal Consultation Document in line with their decisions.

Appraisal of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [ID1098]

Part 1 – Open session

17. The Chair welcomed the invited experts: Peter Clark, Janette Greenhalgh, and Angela Stainthorpe to the meeting and they introduced themselves to the Committee.

18. The Chair welcomed company representatives from Pfizer to the meeting.

19. The Chair asked all Committee members to declare any relevant interests

19.1. Mr Kamal Balakrishnan, Mr Michael Chambers, Mr David Chandler, Ms Gail Coster, Dr Natalie Hallas, Mr John Hampson, Dr Nigel Langford, Professor Andrea Manca, Dr Richard Nicholas, Prof Andrew Renehan, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden, Dr Derek Ward, and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered.
as part of the appraisal of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [ID1098]

19.2. It was noted that Dr Prithviraj Das was excused from the rest of the meeting due to conflicts, as he is employed by Boehringer Ingelheim

20. The Chair asked all NICE Staff to declare any relevant interests.

20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [ID1098]

21. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [ID1098]

22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

24. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.

27. The Committee continued to discuss the clinical and cost effectiveness of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [ID1098]

27.1. The committee decision was based on consensus.

28. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
Appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

Part 2 – Closed session

29. Discussion on confidential information supplied by the company.

30. The Committee continued to discuss the clinical and cost effectiveness of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

30.1. The committee decision was based on consensus.

31. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions

Date, time and venue of the next meeting

Wednesday 21 March 2018 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.